Caris Life Sciences joined the Unicorn Club on May 10, 2021. Headquartered in Irving, Texas, United States, the company develops panomic disease profiling technologies for cancer precision medicine. Its platform leverages AI and machine learning through the proprietary DEAN analytics engine to offer comprehensive tumor profiling, molecular blueprints, and personalized treatment guidance for oncology patients.
Keep reading to learn how Caris Life Sciences built a platform that’s transforming precision cancer care.
What Is Caris Life Sciences and What Does It Do?
Founded in 1996, Caris Life Sciences specializes in precision oncology driven by genomics. The company’s platform integrates molecular profiling, AI, and data analytics to help clinicians tailor cancer therapies to individual patients. Caris aims to accelerate the adoption of precision medicine by combining technology, diagnostics, and actionable insights for clinical decision-making.
How Much Funding Has Caris Life Sciences Raised?
- Series D Round
- Amount Raised: $168 million
- Date: Apr 07, 2025
- Purpose: Expand molecular diagnostics capabilities, enhance AI analytics engine DEAN, and accelerate clinical adoption.
- Earlier Rounds (Seed to Series C)
- Cumulative Funding: ~$1.23 billion
- Key Investors: T. Rowe Price, Silver Lake
- Purpose: Develop genomics technologies, scale laboratory operations, and advance oncology research.
Total Funding Raised: ~$1.23 billion
Latest Funding Date: Apr 07, 2025
Latest Known Valuation: Unicorn status
Employee Count: 1,339 (as of Dec 31, 2022)
Key Investors
- T. Rowe Price
- Details: Global investment management firm focused on growth-oriented companies.
- Focus Areas: Healthcare, genomics, and precision medicine platforms.
- Silver Lake
- Details: Leading technology-focused private equity firm.
- Focus Areas: Healthcare technology, AI-driven platforms, and life sciences innovation.
Where Is Caris Life Sciences’ Headquarters?
Caris Life Sciences is headquartered in Irving, Texas, United States, overseeing diagnostics operations, AI platform development, and precision oncology research.
What’s Next for Caris Life Sciences?
The company aims to expand its AI-driven molecular profiling, accelerate adoption of personalized cancer treatments, and collaborate with healthcare providers and pharma partners globally. Caris plans to enhance clinical decision support through the use of real-world data and advanced analytics, aiming to improve patient outcomes.
Get Investor & Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Caris Life Sciences. Explore insights on genomics, precision oncology, and AI-driven diagnostics shaping the future of healthcare.
Sign up for Free on TexAu to access real-time investor and funding intelligence.
